Remy Hanf
Overview
Explore the profile of Remy Hanf including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
1028
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Schattenberg J, Pares A, Kowdley K, Heneghan M, Caldwell S, Pratt D, et al.
J Hepatol
. 2021 Jan;
74(6):1344-1354.
PMID: 33484775
Background & Aims: Patients with primary biliary cholangitis (PBC) who have an incomplete response to ursodeoxycholic acid remain at risk of disease progression. We investigated the safety and efficacy of...
2.
Harrison S, Ratziu V, Boursier J, Francque S, Bedossa P, Majd Z, et al.
Lancet Gastroenterol Hepatol
. 2020 Aug;
5(11):970-985.
PMID: 32763196
Background: Non-invasive tests that can identify patients with non-alcoholic steatohepatitis (NASH) at higher risk of disease progression are lacking. We report the development and validation of a blood-based diagnostic test...
3.
Chavez-Talavera O, Wargny M, Pichelin M, Descat A, Vallez E, Kouach M, et al.
Metabolism
. 2019 Dec;
103:154042.
PMID: 31785259
Objective: Bile acids (BAs) are signaling molecules controlling lipid and glucose metabolism. Since BA alterations are associated with obesity and insulin resistance, plasma BAs have been considered candidates to predict...
4.
Ratziu V, Harrison S, Francque S, Bedossa P, Lehert P, Serfaty L, et al.
Gastroenterology
. 2016 Feb;
150(5):1147-1159.e5.
PMID: 26874076
Background & Aims: Elafibranor is an agonist of the peroxisome proliferator-activated receptor-α and peroxisome proliferator-activated receptor-δ. Elafibranor improves insulin sensitivity, glucose homeostasis, and lipid metabolism and reduces inflammation. We assessed...
5.
Hanf R, Millatt L, Cariou B, Noel B, Rigou G, Delataille P, et al.
Diab Vasc Dis Res
. 2014 Sep;
11(6):440-7.
PMID: 25212694
We report here the efficacy and safety of GFT505, a novel liver-targeted peroxisome proliferator-activated receptor alpha/delta (PPARα/δ) agonist, in the db/db mouse model of diabetes. Mice were treated with vehicle,...
6.
Cariou B, Hanf R, Lambert-Porcheron S, Zair Y, Sauvinet V, Noel B, et al.
Diabetes Care
. 2013 May;
36(10):2923-30.
PMID: 23715754
Objective: The development of new insulin sensitizers is an unmet need for the treatment of type 2 diabetes. We investigated the effect of GFT505, a dual peroxisome proliferator-activated receptor (PPAR)-α/δ...
7.
Staels B, Rubenstrunk A, Noel B, Rigou G, Delataille P, Millatt L, et al.
Hepatology
. 2013 May;
58(6):1941-52.
PMID: 23703580
Unlabelled: Nonalcoholic fatty liver disease (NAFLD) covers a spectrum of liver damage ranging from simple steatosis to nonalcoholic steatohepatitis (NASH), fibrosis, and cirrhosis. To date, no pharmacological treatment is approved...
8.
Colin S, Briand O, Touche V, Wouters K, Baron M, Pattou F, et al.
Eur Heart J
. 2012 Jul;
34(32):2566-74.
PMID: 22843443
Aims: Peroxisome proliferator-activated receptor (PPAR)-α is a transcription factor controlling lipid metabolism in liver, heart, muscle, and macrophages. Peroxisome proliferator-activated receptor-α activation increases plasma HDL cholesterol and exerts hypotriglyceridaemic actions...
9.
Rubenstrunk A, Hanf R, Hum D, Fruchart J, Staels B
Biochim Biophys Acta
. 2007 Apr;
1771(8):1065-81.
PMID: 17428730
Because of their wide range of actions on glucose homeostasis, lipid metabolism and vascular inflammation, peroxisome proliferator-activated receptors (PPARs) are promising targets for the development of new drugs for the...